APOGEE THERAPEUTICS ($APGE) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of -$1.03 per share, beating estimates of -$1.08 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $APGE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
APOGEE THERAPEUTICS Insider Trading Activity
APOGEE THERAPEUTICS insiders have traded $APGE stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.
Here’s a breakdown of recent trading of $APGE stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 1,750,000 shares for an estimated $133,525,000
- MICHAEL THOMAS HENDERSON (Chief Executive Officer) has made 0 purchases and 17 sales selling 120,000 shares for an estimated $8,657,404.
- CARL DAMBKOWSKI (Chief Medical Officer) has made 0 purchases and 17 sales selling 53,720 shares for an estimated $3,535,452.
- JANE HENDERSON (Chief Financial Officer) has made 0 purchases and 11 sales selling 17,500 shares for an estimated $1,268,275.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
APOGEE THERAPEUTICS Hedge Fund Activity
We have seen 130 institutional investors add shares of APOGEE THERAPEUTICS stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 1,576,626 shares (+324.4%) to their portfolio in Q4 2025, for an estimated $119,003,730
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,554,546 shares (+107879.7%) to their portfolio in Q4 2025, for an estimated $117,337,132
- FMR LLC added 1,308,576 shares (+18.9%) to their portfolio in Q4 2025, for an estimated $98,771,316
- POINT72 ASSET MANAGEMENT, L.P. removed 1,230,377 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $48,882,878
- BLACKROCK, INC. added 1,097,968 shares (+40.9%) to their portfolio in Q4 2025, for an estimated $82,874,624
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,055,464 shares (-81.8%) from their portfolio in Q3 2025, for an estimated $41,933,584
- PERCEPTIVE ADVISORS LLC added 978,662 shares (+72.4%) to their portfolio in Q4 2025, for an estimated $73,869,407
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
APOGEE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $APGE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/06/2026
- Stephens & Co. issued a "Overweight" rating on 12/17/2025
- Deutsche Bank issued a "Buy" rating on 12/10/2025
- Craig-Hallum issued a "Buy" rating on 11/03/2025
- Mizuho issued a "Outperform" rating on 10/21/2025
- RBC Capital issued a "Outperform" rating on 09/25/2025
To track analyst ratings and price targets for APOGEE THERAPEUTICS, check out Quiver Quantitative's $APGE forecast page.
APOGEE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $APGE recently. We have seen 6 analysts offer price targets for $APGE in the last 6 months, with a median target of $104.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $83.0 on 01/22/2026
- Julian Harrison from BTIG set a target price of $137.0 on 01/06/2026
- Sudan Loganathan from Stephens & Co. set a target price of $95.0 on 12/17/2025
- David Hoang from Deutsche Bank set a target price of $103.0 on 12/10/2025
- Adam Vogel from Craig-Hallum set a target price of $109.0 on 11/03/2025
- Joseph Catanzaro from Mizuho set a target price of $105.0 on 10/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
